Therefore, specific small molecule inhibitors such as KMU-3 identified in this study are useful leads for future drug development efforts for prevention and/or treatment of obesity and/or obesity-related disease in which overexpression of leptin, RBP4, and/or RANTES plays pathological roles. This evidence concerns the gene RBP4 and obesity due to melanocortin 4 receptor deficiency.